CLSH
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
CLS Holdings USA (CLSH) has been assigned a Neutral rating, aligning with a composite score of 42.1 and a moderate conviction level of 2 out of 5. The overarching stability in financial condition does not incline towards either bullish or bearish sentiment. The regulatory pillar stands as the strongest contributor, given its robust scoring relative to fundamentals, market conditions, and editorial coverage. A regulatory score close to the median effectively offsets weaker market impressions resulting from lack of trading data.
An examination of the company's fundamentals reveals a year-over-year decline in revenue, contributing to a negative operating margin. Despite CLS Holdings USA achieving gross margins that suggest strong price controls, its market capitalization remains modest, reflecting its current market tier. The firm benefits from a relatively secure financial footing indicated by a healthy cash burn ratio. With no enforcement issues recorded and its compliance posture under US jurisdiction maintaining a satisfactory score, there remains structural assurance on the regulatory front despite the absence of recent filings.
Moving forward, the regulatory environment will continue to play a pivotal role in influencing the investment narrative for CLS Holdings USA. Given the evolving legislative landscape and its direct influence on operations, monitoring regulatory developments becomes increasingly critical. Further, ensuring timely and consistent filing practices will enable clarity and enhance investor confidence. Future adjustments in the regulatory domain could offer significant opportunities for both risk mitigation and strategic advantage.
- SEC CIK
- 0001522222
- Website
- Company website
- Market cap
- $5.9M
- Enterprise value
- $10.6M
- P/E ratio
- 3.6
- Price to book
- 0.36
- Price to sales
- 0.34
- EV / EBITDA
- 2.24
- Revenue (TTM)
- $17.5M
- Gross profit (TTM)
- $7.3M
- EBITDA
- $-815K
- Operating margin
- -10.2%
- Profit margin
- 2.6%
- Rev growth YoY
- -21.8%
- Return on equity
- -631.7%
- Return on assets
- -11.8%
- EPS (TTM)
- $0.01
- Wall St. target price
- $0.08
- Shares outstanding
- 164.7M
- Insider ownership
- 79.1%
- Beta
- 1.18
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for CLSH (CLSH)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for CLSH (CLSH), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CLSH are maintained by Cannabis Investor News and refreshed throughout the trading day.